Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +11.41%
#3 Meteora Meteora +10.48%
#4 Unit Pump Unit Pump +10.28%
#5 Pump.fun Pump.fun +10.28%
#6 eCash eCash +8.55%
#7 OPENLOOT OPENLOOT +8.41%
#8 Glidr Glidr +6.76%
#9 Ergo Ergo +6.51%
#10 Qkacoin Qkacoin +6.46%
Coin of the day
PulseChain PulseChain
設定
言語
日本
通貨
USD
テーマ
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
株式のランク #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
株価
$0.55
最終同期: 2025-02-11
時価総額
$28.90M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Marinus Pharmaceuticals, Inc. (MRNS)

カテゴリー

Healthcare
Marinus Pharmaceuticals, Inc.（MRNS）の配当利回りの履歴
Marinus Pharmaceuticals, Inc.（銘柄コード: MRNS）の配当利回り（TTM）は2022-12-31時点で0.00%です。
過去5年間の平均配当利回り: 0.00%
Marinus Pharmaceuticals, Inc.（MRNS）の2012から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
年 配当利回り 変化
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
類似企業または競合他社の配当利回り（TTM）
企業 配当利回り 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH